Common early experiences include: Reduced appetite : Many people notice decreased hunger and earlier satiety during meals within days of the first injection or dose Mild gastrointestinal symptoms : Nausea (affecting 2040% of patients), occasional vomiting, or changes in bowel habits are usually mild and transient Injection site reactions : Minor redness, itching, or discomfort at injection sites is common but typically resolves quickly Fatigue : Some individuals report feeling more tired initially as their body adjusts to reduced calorie intake By weeks 24 , appetite suppression typically becomes more pronounced, and patients often find it easier to adhere to portion control and dietary modifications
In patients with chronic kidney disease, reduced reabsorption of carnitine can affect the availability of carnitine in muscles, leading to skeletal muscle atrophy and decreased exercise endurance [262]
MOTS-c is added at Week 5 with two common approaches: intermittent (most common) or low-dose daily
Their effectiveness has been recognized with FDA approval thanks to their capacity for enhancing weight control alongside improving blood sugar regulation
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)